Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Sanara MedTech Inc. is the target of MiMedx Group’s proposed acquisition for $35 per Sanara share: $33 in cash and 0.4735 shares of MiMedx common stock, assigned a value of $2.00 per share using MiMedx’s average closing price of $4.22 over the five consecutive trading days through and including July 28, 2026. The proposed transaction’s total enterprise value is approximately $350 million, and the offer was described as a 46% premium to Sanara’s 30-day volume weighted average share price as of July 28, 2026.
Sanara stockholders have approved the transaction, while MiMedx says FTC clearance remains the last major hurdle to closing following the FTC’s Second Request. MiMedx’s $300 million first-lien senior secured term loan financing is tied to closing, has a six-year term, and carries initial interest at Term SOFR plus 6.25%. Sanara reported 2025 net revenue of $103 million and Adjusted EBITDA of $17 million.
Sanara MedTech Inc. and MiMedx Group each received a Federal Trade Commission (FTC) request for additional information and documents on October 15, 2026, as part of the FTC’s review of their proposed merger. Under the merger agreement, MiMedx’s wholly owned Merger Subsidiary would merge into Sanara, which would survive as MiMedx’s wholly owned subsidiary, subject to the agreement’s terms and conditions.
The Second Request extends the Hart-Scott-Rodino Act waiting period until 30 days after the parties substantially comply, unless the parties voluntarily extend the period or the FTC terminates it earlier. Completion remains subject to expiration or termination of that waiting period and satisfaction or waiver of the merger agreement’s other closing conditions. Sanara said it continues to work constructively with the FTC.
Sanara MedTech Inc. (SMTI) and MiMedx Group, Inc. each received a Second Request from the Federal Trade Commission on October 15, 2026, in connection with their proposed merger. Under the merger agreement, MiMedx’s wholly owned Mustang Merger Sub, Inc. would merge into Sanara, with Sanara surviving as a wholly owned subsidiary of MiMedx.
The Second Request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, unless the parties voluntarily extend the period or the FTC terminates it earlier. Completion remains subject to expiration or termination of that waiting period and satisfaction or waiver of the merger agreement’s other closing conditions. Sanara said it continues to work constructively with the FTC.
Sanara MedTech Inc. and MiMedx Group, Inc. each received a Federal Trade Commission (FTC) Second Request on October 15, 2026, for information and documents relating to their proposed merger. The request extends the Hart-Scott-Rodino Act waiting period until 30 days after the parties substantially comply, unless they voluntarily extend the period or the FTC terminates it earlier.
Under the merger agreement, MiMedx’s wholly owned merger subsidiary is to merge into Sanara, which would survive as MiMedx’s wholly owned subsidiary. Completion remains subject to the waiting period ending or being terminated and the satisfaction or waiver of the merger agreement’s other closing conditions. MiMedx said it continues to work constructively with the FTC.
Sanara MedTech Inc. reported that shareholders approved Proposals 1 and 2 at its September 30, 2026 special meeting. As of the September 1, 2026 record date, 9,188,035 common shares were outstanding; 6,411,427 shares, approximately 69.78%, were present in person or by proxy, constituting a quorum. Proposal 1 received 6,372,989 votes for, 1,944 against and 36,494 abstentions. Proposal 2 received 5,841,470 votes for, 75,247 against and 494,710 abstentions. Proposal 3 was not submitted because sufficient votes had been cast to approve Proposal 1.
Separately, MiMedx, in consultation with Sanara, withdrew its HSR notification on September 11, 2026, and refiled it on September 15 to provide the Federal Trade Commission additional review time. The refiling began a new 30-calendar-day waiting period, set to expire at 11:59 p.m. Eastern Time on October 15, 2026, unless extended or earlier terminated. The merger remains subject to satisfaction or waiver of the other conditions in the Merger Agreement.
Sanara MedTech Inc. (SMTI) reported that Chief Executive Officer and director Yon Seth D had 3,661 shares of common stock withheld on September 15, 2026 to satisfy tax withholding obligations in connection with the annual vesting of 9,521 shares of restricted stock. The shares were withheld by the issuer at a value of $35.11 per share, with 105,885 shares of common stock held directly by the reporting person after this transaction. No shares were issued or sold into the market, and no Rule 10b5-1 trading plan is reported.
Sanara MedTech Inc. (symbol: SMTI) is the issuer of record for a Form DEFM14A filing submitted to the SEC.
Sanara MedTech Inc. (SMTI) announced that it has entered into a definitive agreement for MiMedx Group, Inc. to acquire Sanara, aiming to form a leading regenerative medicine company across multiple surgical subspecialties. The combination is described as complementary, expanding the portfolio of regenerative products supported by clinical evidence.
The transaction is expected to close by the end of the year, subject to customary closing conditions, including regulatory approvals and approval of Sanara’s stockholders. Until closing, Sanara and MiMedx will continue to operate as separate companies and existing distributor agreements and day-to-day contacts remain unchanged. Sanara highlights integration planning efforts and directs questions to a dedicated integration email. The communication also includes extensive forward-looking statement cautions and explains that a registration statement on Form S-4 with a joint proxy statement/prospectus will be filed with the SEC, which investors are urged to read when available.
Sanara MedTech Inc. reported higher sales for the quarter and six months ended June 30, 2026, while essentially breaking even year-to-date after winding down its THP segment. Net revenue rose to $28.1 million in the quarter and $55.9 million for six months, driven mainly by soft tissue repair products. Operating income from continuing operations was $1.8 million for the quarter and $4.4 million year-to-date, but higher interest and equity-method losses produced a quarterly net loss attributable to shareholders of $452,864. For the six months, net income attributable to shareholders was $6,093, compared with a significant loss a year earlier, as discontinued THP operations no longer weigh on results.
Cash from operating activities was $(426,935) for the six months, reflecting lower accrued bonuses and higher interest payments. Cash and cash equivalents were $15.4 million and long-term debt under the CRG Term Loan was $46.5 million, with annual minimum revenue covenants rising to $85.0 million for 2026. Shareholders’ equity increased to $7.9 million, supported by share-based compensation and reduced accumulated deficit.
MiMedx Group, Inc. filed an amendment to its prior report on the merger with Sanara MedTech Inc. to correct the allocation of termination fees: Sanara would owe $9,660,336.00 in specified circumstances and MiMedx would owe $22,540,785.00 if it fails to close when required.
Under the Agreement and Plan of Merger, Sanara will merge into a MiMedx subsidiary and become a wholly owned subsidiary of MiMedx. Each share of Sanara common stock (other than excluded and appraisal shares) will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock, with the stock portion valued at $2.00 per share based on a five‑day average. Sanara equity awards will be cashed out based on this consideration.
The transaction is subject to Sanara stockholder approval, antitrust clearance, effectiveness of a Form S‑4 registration statement, Nasdaq listing of the MiMedx shares, and customary conditions, including no material adverse effect on Sanara. MiMedx obtained a $300.0 million first‑lien senior secured term loan commitment to finance the merger and refinance its existing credit agreement. A voting agreement covers Sanara holders representing about 38.9% of the voting power.